{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} 102: Dyslipidemia: Going Beyong the Current Treatment Options


Audio Session and Presentation Slides from National Conference Nurse Practitioners 2017

The goal of this activity is to improve management of dyslipidemia and develop strategies for the initiation of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as well as address patient-related concerns. You'll be able to increase your knowledge regarding the ability to assess patients with dyslipidemia to evaluate their need for treatment beyond statins and will have greater competence related to the identification of practical strategies used to initiate treatment with PCSK9 inhibitors, manage side effects, and address patient-related concerns.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Discuss 2016 Updated ACC Guidelines, NLA and other recommendations for dyslipidemia management.
  2. Recall that statin therapy is the first line medication treatment for risk reduction.
  3. Discuss considerations for addition of "other" classes of lipid lowering medication when combination medication therapy is warranted.
Price: $17.95


  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223. (CE Broker Course #20-591743)

Awarded Advanced Pharmacology Hours

Test Code: ncnpfall2017S102A
Published: October 2017
Expires: 9/6/2019
Passing Score: 1/1 (100%)
Authors: Joyce L. Ross MSN CRNP CLS FNLA FPCNA, Clinical Specialist, Cardiovascular Risk Intervention Program